Touchlight’s dbDNA™ can enable significant cost savings for AAV gene therapy developers, accelerating the drive towards more cost-effective AAV gene therapies. An independent analysis conducted by Decisional Points Limited revealed that switching from pDNA to dbDNA without transfection process optimisation, reduced CoGs per dose by 14%. Further CoGs savings beyond those modelled in this study could be achieved when switching to dbDNA due to the elimination of the need for bacterial MCB manufacture and efficiencies in downstream processing due to improvements in % full capsids.​

Download the poster to see the full cost savings analysis.